Znanstveni rad - Izvorni znanstveni rad
Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients
Croatian Medical Journal, 58 (2017), 1; 40-48. https://doi.org/10.3325/cmj.2017.58.40

Pejša, Vlatko; Prka, Željko; Lucijanić, Marko; Mitrović, Zdravko; Piršić, Mario; Jakšić, Ozren; Ajduković, Radmila; Kušec, Rajko

Citirajte ovaj rad

Pejša, V., Prka, Ž., Lucijanić, M., Mitrović, Z., Piršić, M., Jakšić, O. ... Kušec, R. (2017). Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croatian Medical Journal, 58. (1), 40-48. doi: 10.3325/cmj.2017.58.40

Pejša, Vlatko, et al. "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients." Croatian Medical Journal, vol. 58, br. 1, 2017, str. 40-48. https://doi.org/10.3325/cmj.2017.58.40

Pejša, Vlatko, Željko Prka, Marko Lucijanić, Zdravko Mitrović, Mario Piršić, Ozren Jakšić, Radmila Ajduković i Rajko Kušec. "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients." Croatian Medical Journal 58, br. 1 (2017): 40-48. https://doi.org/10.3325/cmj.2017.58.40

Pejša, V., et al. (2017) 'Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients', Croatian Medical Journal, 58(1), str. 40-48. doi: 10.3325/cmj.2017.58.40

Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, i sur.. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croatian Medical Journal [Internet]. 28.02.2017. [pristupljeno 03.11.2024.];58(1):40-48. doi: 10.3325/cmj.2017.58.40

V. Pejša, et al., "Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients", Croatian Medical Journal, vol. 58, br. 1, str. 40-48, Veljača 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:668434. [Citirano: 03.11.2024.]